Skip to main content

Prostate Cancer Clinical Trials

Review the prostate cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 548

Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients with Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide with Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Stereotactic Body Radiation Therapy for the Treatment of Patients with Advanced Prostate Cancer, PRORAD-5 Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Pembrolizumab with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Carboplatin and Cabazitaxel versus Lutetium-177-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CATCH-177 Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
XL092 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, PRO-XL Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Neoadjuvant Leuprolide Acetate and Darolutamide with Pembrolizumab, Followed by Adjuvant Pembrolizumab for the Treatment of Intermediate or High-Risk Localized and Locally Advanced Prostate Adenocarcinoma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Leuprolide Acetate Alone versus in Combination with 177Lu-PSMA-617, with or without Abiraterone Acetate and Prednisone, for the treatment of Recurrent or De Novo Low Volume Metastatic Hormone-Sensitive Prostate Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Ivonescimab for the Treatment of Patients with Locally Advanced, Unresectable and/or Metastatic Cutaneous Squamous Cell Cancer and Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
High Dose Rate Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Evaluation of 177Lu rhPSMA-10.1 and Degarelix before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer, Nautilus Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Cell Therapy (STEAP1 CART) with Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Abemaciclib before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California